检索结果-南通市图书馆

Persistent fifth aortic arch stenosis associated with type A interruption of the aortic arch: a report of six cases

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2019年第12期132卷 1482-1484页

作者： lin Zheng Yong-Li Cao rong-Chang wu jian guo Ning Ma Fang-Yun Wang xin Zhang Yun Peng Department of Echocardiography Beijing Children's HospitalCapital Medical UniversityNational Center for Children's HealthBeijing 100045China Department of Radiology Beijing Children's HospitalCapital Medical UniversityNational Center for Children's HealthBeijing 100045China Department of Cardiac Surgery Beijing Children's HospitalCapital Medical UniversityNational Center for Children's HealthBeijing 100045China

Persistent fifth aortic arch (PFAA) is a rare congenital cardiovascular malformation that occurs when the pharyngeal fifth aortic arch does not degenerate during the embryonic period. The first case of PFAA was described in an autopsy specimen in 1969.[1] In 1973, the persistence of a left fifth aortic arch was first reported.[2] Since then, several case reports have described PFAA in different forms. PFAA stenosis associated with type A interruption of the aortic arch (type-A IAA) is most common in clinical practice and requires surgical intervention. From 2013 to 2018, six cases [Table 1 and Table 2] were diagnosed using echocardiography and computed tomography angiography (CTA). Five cases were successfully treated with surgery and followed-up. The purpose of this study was to summarize the clinical characteristics and diagnostic features of PFAA stenosis associated with type-A IAA to improve its diagnostic accuracy and allow for complete pre-operative preparation and proper treatment.

关键词： Persistent fifth aortic arch stenosis type A interruption six cases

Safety and efficacy of thalidomide in patients with transfusiondependentβ-thalassemia:a randomized clinical trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第12期6卷 3723-3729页

作者： jiang-ming Chen wei-jian Zhu Jie Liu Gui-Zhen Wang Xiao-Qin Chen Yun Tan wei-wei Xu Li-wei Qu Jin-Yan Li Huan-Ju Yang Lan Huang Ning Cai wei-Da Wang Ken Huang jian-Quan Xu guo-Hui Li Sheng He Tian-Ying Luo Yi Huang song-Hua Liu Wen-Qiang wu Qi-Yang Lu Mei-Guang Zhou Shu-Ying Chen rong-Lan Li Mei-ling Hu Ying Huang Jin-Hua wei Jun-Min Li Sai-Juan Chen Guang-Biao Zhou Department of Hematology Wuzhou Gongren HospitalWuzhou 543001 GuangxiChina Department of Hematology Zhuhai People’s Hospital(Zhuhai Hospital Affiliated with Jinan University)Zhuhai 541000 GuangdongChina State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Reproductive Medicine The First Affiliated Hospital of Hebei North UniversityZhangjiakou 075000 HebeiChina State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineMedical Oncology DepartmentSun Yat-Sen University Cancer CenterGuangzhou 510060 GuangdongChina State Key Laboratory of Medical Genomics Shanghai Institute of HematologyNational Research Center for Translational MedicineRuijin Hospital Affiliated with Shanghai Jiao Tong University School of MedicineShanghai 200025China State Key Laboratory of Membrane Biology Institute of ZoologyChinese Academy of Sciences&University of Chinese Academy of SciencesBeijing 100101China Department of Pediatrics Affiliated Hospital of Youjiang Medical University for NationalitiesBaise City 533000 GuangxiChina Department of Hematology Yulin Guinan HospitalYulin 537005 GuangxiChina Department of neurology Wuzhou Gongren HospitalWuzhou 543001 GuangxiChina Guangxi Key Laboratory of Basic Research on Birth Defects Prevention and Treatment Guangxi Zhuang Autonomous Region Women and Children Health Care HospitalNanning 530000 GuangxiChina Department of Hematology Guigang People’s HospitalGuigang 537100 GuangxiChina Department of Hematology Hospital of Traditional Chinese Medicine of Wuzhou CityWuzhou 543002 GuangxiChina Department of Hematology Wuzhou Red Cross HospitalWuzhou 543002 GuangxiChina Department of Hematology Hechi People’s HospitalHechi City 547000 GuangxiChina

Thalidomide inducesγ-globin expression in erythroid progenitor cells,but its efficacy on patients with transfusion-dependentβ-thalassemia(TDT)remains *** this phase 2,multi-center,randomized,double-blind clinical trial,we aimed to determine the safety and efficacy of thalidomide in TDT patients.A hundred patients of 14 years or older were randomly assigned to receive placebo or thalidomide for 12 weeks,followed by an extension phase of at least 36 *** primary endpoint was the change of hemoglobin(Hb)level in the *** secondary endpoints included the red blood cell(RBC)units transfused and adverse *** the placebo-controlled period,Hb concentrations in patients treated with thalidomide achieved a median elevation of 14.0(range,2.5 to 37.5)g/L,whereas Hb in patients treated with placebo did not significantly *** the 12 weeks,the mean RBC transfusion volume for patients treated with thalidomide and placebo was 5.4±5.0 U and 10.3±6.4 U,respectively(P<0.001).Adverse events of drowsiness,dizziness,fatigue,pyrexia,sore throat,and rash were more common with thalidomide than *** the extension phase,treatment with thalidomide for 24 weeks resulted in a sustainable increase in Hb concentrations which reached 104.9±19.0 g/L,without blood *** increase in Hb concentration and reduction in RBC transfusions were associated with nonβ0/β0 and HBS1L-MYB(rs9399137 C/T,C/C;rs4895441 A/G,G/G)*** results demonstrated that thalidomide is effective in patients with TDT.

关键词： transfusion patients thalidomide

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China(RWE-PCSK study)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2021年第4期18卷 261-270页

作者： Yu-Qi LIU Dan-Dan LI Meng CHAI Hong-Liang CONG Xiao-Qiang CONG Jun DAI rong-Pin DU ming GAO Jin-Cheng guo Yan-Qing guo Xiao-jian HONG rong-Chong HUANG Feng-Shun JIA Jia-Yu LI Qing LI Jia-Mei LIU xin-Ping LIU Yu-guo LIU Hong-Gang NIE Bing SHAO Xiao-Yu SHEN Hai-Qing song Yi-Jun song Li-Jun WANG Shuo WANG Dong-Mei wu Jing XIA Zhi-Yong YANG Hong-Ying YU Hui ZHANG Tie-Mei ZHANG Ji-Yi ZHAO Liang-Chen ZHAO ming-Qi ZHENG Yun-Dai CHEN Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijing Institute of Heart Lung and Blood Vessel DiseaseBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic DiseaseClinical Center for Coronary Heart DiseaseCapital Medical UniversityBeijingChina Department of Cardiology Tianjin Chest HospitalTianjinChina Department of Cardiology the First Hospital of Jilin UniversityChangchunChina Department of Cardiology Fuwai HospitalNational Center for Cardiovascular DiseaseChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Cardiology Hebei People’s HospitalShijiazhuangChina Department of Cardiology Kailuan General HospitalHebei Union UniversityTangshanChina Department of Cardiology Beijing Luhe HospitalCapital Medical UniversityBeijingChina Department of Cardiology Shanxi Cardiovascular HospitalTaiyuanChina Department of Cardiology the Fourth Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Cardiology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Cardiology Tangshan Worker’s HospitalTangshanChina Department of Cardiology China-Japan Friendship Hospital Affiliated Jilin UniversityChangchunChina Department of Cardiology Handan Central HospitalHebeiChina Heart Center Beijing Key Laboratory of HypertensionBeijing Chao-Yang HospitalCapital Medical UniversityBeijingChina Department of Cardiology the First Affiliated Hospital of Dalian Medical UniversityLiaoningChina Department of Cardiology the Second Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Cardiology the Second Affiliated Hospital of Shenyang Medical CollegeShenyangChina Department of Cardiology the Second Hospital of Shanxi Medical UniversityTaiyuanChina Department of Neurology Xuanwu Hospital Capital Medical UniversityBeijingChina Department of Neurology Tianjin Medical University Gen

BACKGROUND The efficacy and safety of proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitors were confirmed by several clinical trials, but its effectiveness in routine clinical practice in China has not been evaluated. This study aims to describe the real world effectiveness of PCSK-9 inhibitors combined with statins compared with statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease(ASCVD).METHODS This is a multi-center observational study, enrolled patients from 32 hospitals who underwent percutaneous coronary intervention(PCI) from January to June in 2019. There are 453 patients treated with PCSK-9 inhibitors combined with statins in PCSK-9 inhibitor group and 2,610 patients treated with statins-based lipid lowering therapies in statins-based group. The lipid control rate and incidence of major adverse cardiovascular events(MACE) over six months were compared between two groups.A propensity score-matched(PSM) analysis was used to balance two groups on confounding factors. Survival analysis using Kaplan-Meier methods was applied for *** In a total of 3,063 patients, 89.91% of patients had received moderate or high-intensity statins-based therapy before PCI, but only 9.47% of patients had low-density lipoprotein cholesterol(LDL-C) levels below 1.4 mmol/L at baseline. In the PSM selected patients, LDL-C level was reduced by 42.57% in PCSK-9 inhibitor group and 30.81%(P < 0.001) in statins-based group after six months. The proportion of LDL-C ≤ 1.0 mmol/L increased from 5.29% to 29.26% in PCSK-9 inhibitor group and 0.23% to 6.11% in statins-based group, and the proportion of LDL-C ≤ 1.4 mmol/L increased from 10.36% to 47.69% in PCSK-9 inhibitor group and 2.99% to 18.43% in statins-based group(P < 0.001 for both). There was no significant difference between PCSK-9 inhibitor and statins-based treatment in reducing the risk of MACE(hazard ratio = 2.52, 95% CI: 0.49-12.97, P = 0.250).CONCLUSIONS In the real

关键词： LDL RWE-PCSK study Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high r

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第7期7卷 2533-2544页

作者： Xi Shi Zihao Wang wei Ren Long Chen Cong Xu Menghua Li Shiyong Fan Yuru Xu Mengbing Chen Fanjun Zheng Wenyuan Zhang xinbo Zhou Yue Zhang Shiwei Qiu Liyuan wu Peng Zhou xinze Lv Tianyu Cui Yuehua Qiao Hui Zhao weiwei guo wei Chen song Li wu Zhong jian lin Shiming Yang Department of Pharmacy Peking University Third HospitalBeijingChina Artificial Auditory Laboratory of jiangsu Province Xuzhou Medical UniversityXuzhouChina National Engineering Research Center for the Emergency Drug Beijing Institute of Pharmacology and ToxicologyBeijingChina College of Otolaryngology Head and Neck Surgery Chinese PLA General HospitalBeijingChina National Clinical Research Center for Otolaryngologic Diseases BeijingChina Key Lab of Hearing Science Ministry of EducationBeijingChina Beijing Key Lab of Hearing Impairment for Prevention and Treatment BeijingChina Synthetic and Functional Biomolecules Center Beijing National Laboratory for Molecular SciencesKey Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of EducationCollege of Chemistry and Molecular EngineeringInnovation Center for GenomicsPeking UniversityBeijingChina

Inner ear disorders are a cluster of diseases that cause hearing loss in more than 1.5 billion people ***,the presence of the blood-labyrinth barrier(BLB)on the surface of the inner ear capillaries greatly hinders the effectiveness of systemic drugs for prevention and intervention due to the low permeability,which restricts the entry of most drug compounds from the bloodstream into the inner ear ***,we report the finding of a novel receptor,low-density lipoprotein receptor-related protein 1(LRP1),that is expressed on the BLB,as a potential target for shuttling therapeutics across this *** a proof-ofconcept,we developed an LRP1-binding peptide,IETP2,and covalently conjugated a series of model small-molecule compounds to it,including potential drugs and imaging *** compounds were successfully delivered into the inner ear and inner ear lymph,indicating that targeting the receptor LRP1 is a promising strategy to enhance the permeability of the *** discovery of the receptor LRP1 will illuminate developing strategies for crossing the BLB and for improving systemic drug delivery for inner ear disorders.

关键词： drugs prevention barrier

Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2024年第6期30卷 489-498页

作者： CAO Ni-da ZHU Xiao-hong MA Fang-qi XU Yan DONG Jia-huan QIN Meng-meng LIU Tian-shu ZHU Chun-chao guo wei-jian DING Hong-hua guo Yuan-biao LIU Li-kun song Jin-jie wu Ji-ping CHENG Yue-lei ZENG lin ZHAO Ai-guang Oncology Department I Longhua Hospital Shanghai University of Traditional Chinese MedicineShanghai200032China Oncology Department Zhongshan HospitalFudan UniversityShanghai200032China Gastrointestinal Surgery Department Renji HospitalShanghai Jiaotong University School of MedicineShanghai200127China Oncology Department Fudan University Shanghai Cancer CenterShanghai200032China Oncology Department Shanghai General HospitalShanghai Jiaotong University School of MedicineShanghai200080China Traditional Chinese Medicine Department Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai200025China Oncology Department Shanxi Traditional Chinese Medicine HospitalTaiyuan030012China Oncology Department Xiyuan HospitalChina Academy of Chinese Medical ScienceBeijing102445China Oncology Department Yunnan Province Hospital of Traditional Chinese MedicineKunming650021China Oncology Department Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai201203China Shanghai NewCore Biotechnology Co. Ltd.Shanghai200240China

Objective To describe the treatment patterns and survival status of advanced gastric cancer(AGC)in China in the past two decades,and objectively evaluate the impact of standardized Chinese medicine(CM)treatment on the survival of AGC *** This multicenter registry designed and propensity score analysis study described the diagnosis characteristics,treatment-pattern development and survival status of AGC from 10 hospitals in China between January 1,2000 and July 31,*** survival(OS)was evaluated between non-CM cohort(standard medical treatment)and CM cohort(integrated standard CM treatment≥3 months).Propensity score matching(PSM)and inverse probability of treatment weighting(IPTW)were performed to adjust any difference in average outcomes for *** A total of 2,001 patients histologically confirmed locally advanced and/or metastasis stomach and gastroesophageal junction adenocarcinoma were *** them,1,607 received systemic chemotherapy,215(10.74%)accepted molecular targeted therapy,44(2.2%)received checkpoint inhibitor therapy,and 769(38.43%)received ***-drug regimen was the main choice for first-line treatment,with fluoropyrimidine plus platinum as the most common regimen(530 cases,60.09%).While 45.71%(16 cases)of patients with HER2 amplification received trastuzumab in *** application of apatinib increased(33.33%)in *** application of checkpoint inhibitors has increased since *** analysis showed that Lauren mixed type(P=0.017),cycles of first-line treatment>6(P=0.000),CM(P=0.000),palliative gastrectomy(P=0.000),trastuzumab(P=0.011),and apatinib(P=0.008)were independent prognostic factors for the OS of *** PSM and IPTW,the median OS of CM cohort and non-CM cohort was 18.17 and 12.45 months,respectively(Pline *** CM treatment was an independent

关键词： advancedgastriccancer real-world study treatment pattern survival analysis Chinese medicine

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs.3 doses in young women

在线全文

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2020年第4期63卷 582-591页

作者： Yue-Mei Hu Meng guo Chang-Gui Li Kai Chu Wen-Gang He Jing Zhang jian-Xiang Gu Juan Li Hui Zhao Xiang-Hong wu Bi-Zhen lin Zhi-Jie lin xing-Mei Yao Ya-Fei Li Fei-Xue wei Yue Huang Ying-Ying Su Feng-Cai Zhu Shou-Jie Huang Hui-rong Pan Ting wu Jun Zhang Ning-Shao Xia jiangsu Provincial Center for Disease Control and Prevention Nanjing 210009China The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics National Institute of Diagnostics and Vaccine Development in Infectious DiseasesCollaborative Innovation Center of Biologic ProductsSchool of Public HealthXiamen UniversityXiamen 361102China National Institute for Food and Drug Control Beijing 102629China Sheyang Center for Disease Control and Prevention Sheyang 244300China Xiamen Innovax Biotech Company Xiamen 361022China

A new HPV-16/18 bivalent vaccine expressed by the Escherichia coli has been proven to be efficacious in adult women.A randomized,immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in *** aged 9–14 years were randomized to receive 2 doses at months 0 and 6(n=301)or 3 doses at months 0,1 and 6(n=304).Girls aged 15–17 years(n=149)and women aged 18–26 years(n=225)received 3 *** objectives included noninferiority analysis of the IgG geometric mean concentration(GMC)ratio(95%CI,lower bound>0.5)to HPV-16 and HPV-18 at month 7 in girls compared with *** the per-protocol set,the GMC ratio of IgG was noninferior for girls aged 9–17 years receiving 3 doses compared with women(1.76(95%CI,1.56,1.99)for HPV-16 and 1.93(95%CI,1.69,2.21)for HPV-18)and noninferior for girls aged 9–14 years receiving 2 doses compared with women(1.45(95%CI,1.25,1.62)for HPV-16 and 1.17(95%CI,1.02,1.33)for HPV-18).Noninferiority was also demonstrated for neutralizing *** immunogenicity of the HPV vaccine in girls receiving 3 or 2 doses was noninferior compared with that in young adult women.

关键词： immunobridging noninferiority human papillomavirus vaccine Escherichia coli girls

Isospin Effect of Fragmentation Reaction on the Isotopic Distribution Producedin Intermediate Energy Heavy Ion Collisions

在线全文

学校读者我要写书评

暂无评论

Chinese Physics Letters 2000年第4期17卷 267-269页

作者： FANG De-Qing SHEN Wen-Qing FENG Jun CAI Xiang-Zhou WANG jian-song SU Qian-Min MA Yu-Gang Zhu Yong-tai LI song-lin wu He-Yu GOU Quan-bu JIN Gen-ming ZHAN Wen-Long guo Zhong-Yan XIAO guo-Qing Shanghai Institute of Nuclear Research Chinese Academy of SciencesShanghai 201800 Institute of Modern Physics Chinese Academy of SciencesLanzhou 730000

Fragments produced in the reaction of 60 MeV/n^(18)O on Be have been measured *** isotopic distribution of fragmentation reaction is well reproduced by a modified statistical abrasion-ablation model It is predicted that the isotopic distribution shifts toward the neutron rich side for neutron rich projectile,but this isospin effect decreases with the increase of the atomic number difference Z-Z_(A)and disappears at last,where Z and Z_(A)are atomic numbers of the isotopic distribution and the projectile respectively.

关键词： distribution atomic Collisions

Was chicken domesticated in northern China?New evidence from mitochondrial genomes

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science Bulletin 2018年第12期63卷 743-746页

作者： Xun-He Huang Ya-jiang wu Yong-Wang Miao Min-Sheng Peng xing Chen Dan-lin He Chatmongkon Suwannapoom Bing-Wang Du Xian-Yao Li Zhuo-Xian Weng Si-Hua Jin Jiao-Jiao song ming-Shan Wang Jie-Bo Chen wei-Na Li Newton Otieno Otecko Zhao-Yu Geng Xiang-Yong Qu Yan-Ping wu Xiu-rong Yang Jie-Qiong Jin jian-lin Han Fu-Sheng Zhong Xi-Quan Zhang Ya-Ping Zhang School of Life Sciences.flaying University.Meizhou 514015.China State Key Laboratory for Conservation and Utilization of Bio-resources in Yunnan Yunnan UniversityKunming 650091China Faculty of Animal Science and Technology.Yunnan Agricultural University.Kunming 650201.China State Key Laboratory of Genetic Resources and Evolution and Yunnan Laboratory of Molecular Biology of Domestic Animals.kunming Institute of Zoology.Chinese Academy of Sciences.Kunming 650223.China College of Animal Sciences.South China Agricultural University.Guangzhou 510642.China School of Agriculture and Natural Resources.University of Phayao.Phayao 56000.Thailand College of Agriculture.Guangdong Ocean University.Zhanjiang 524088.China College of Animal Science and Technology.Shandong Agricultural University.Taian 271018.China College of Animal Science and Technology.Hunan Agricultural University.Changsha 410128.China College of Animal Science and Technology.Anhui Agricultural University.Hefei 230036.China Institute of Animal Science.jiangxi Academy of Agricultural Sciences.Nanchang 330200.China College of Animal Science and Technology.Guangxi University.Nanning 530004.China Kunming College of Life Science.University of Chinese Academy of Sciences.Kunming 650204.China Southeast Asia Biodiversity Research Institute.Chinese Academy of Sciences(CAS-SEABRI).Yezin 05282.Myanmar CAAS-ILRI Joint Laboratory on Livestock and Forage Genetic Resources.Institute of Animal Science.Chinese Academy of Agricultural Sciences(CAAS).Beijing 100193.China International Livestock Research Institute(ILRI).Nairobi 00100.Kenya

The timing and location of chicken(Gallus gallus domesticus)domestication have remained controversial for over a century[1].Several researchers have proposed China as one of the early centers for chicken domestication[2].This is based on a few archaeological‘‘chicken"remains discovered in China(Table S1).Recently,one investigation detected mitochondrial DNA(mt DNA)haplotypes

关键词：鸡肉中国染色体驯养证据研究人员职业人员 DNA

SAPT:a synchrotron-based proton therapy facility in Shanghai

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2023年第10期34卷 36-46页

作者： Man-Zhou Zhang De-ming Li Li-Ren Shen Hai-rong Zhang Zhi-ling Chen Han-Wen Du ming Gu Rui Li De-Kang Liu Yue-Hu Pu Jun-Feng Yu jian-Feng Chen Chu Chen Chun-Long guo Hao guo Ge-Yang jiang Zhi-Qiang jiang lin Jin Wen-Jing Li Xiu-Fang Li Ye lin ming Liu Yong-Hao Liu Ya-Juan Liu ming Lv Qing-Ru Mi Lian-Hua Ouyang wei-guo Shi Hang Shu Qi-Sheng Tang Kun Wang Zhi-Shan Wang Jun wu Xiao-Bing wu Jia-Qiang Xu Wen-Zhen Xu Chong-Xian Yin Cheng Yu Ren-Xian Yuan Qi-Bing Yuan Hai-Qun Zhang Miao Zhang Wen-Zhi Zhang Li-Ying Zhao wei-Min Zhou Shou-Xian Fang Xi-Dong Sun Zhen-Tang Zhao Shanghai Institute of Applied Physics Chinese Academy of SciencesShanghai 201800China Shanghai Advanced Research Institute Chinese Academy of SciencesShanghai 201204China APACTRON Particle Equipment Co. Ltd.Shanghai 201815China The Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China

Because of its excellent dose distribution,proton therapy is becoming increasingly popular in the medical application of cancer treatment.A synchrotron-based proton therapy facility was designed and constructed in *** synchrotron,beam delivery system,and other technical systems were commissioned and reached their expected *** a clinical trial of 47 patients was finished,the proton therapy facility obtained a registration certificate from the National Medical Products *** characteristics of the accelerator and treatment systems are described in this article.

关键词： Proton therapy Synchrotron Slow extraction Gantry Beam delivery system